Peptide News Digest

Eisai-Biogen Leqembi Iqlik Weekly SC US, BioMarin-Alesta $275M Oral HPP, J&J Imaavy wAIHA Approval, Haisco-Sentivera License

Eisai-Biogen Leqembi Iqlik weekly SC lecanemab available in US. BioMarin acquires Alesta for $275M oral HPP. J&J Imaavy FDA-approved. Haisco-Sentivera license.

4 stories · Covering industry, regulatory

Editor's Note

Wednesday's biotech news pivots to monoclonal antibody delivery format innovation, rare-disease deal-making, and Chinese biotech US-market partnerships. Eisai and Biogen announced Wednesday August 26, 2026 that once-weekly subcutaneous lecanemab-irmb (Leqembi Iqlik) is now commercially available in the United States for initiation therapy in adults with early Alzheimer's disease (mild cognitive impairment or mild dementia due to AD), representing the anti-amyloid class's substantive transition from twice-monthly intravenous infusion to weekly SC injection and improving patient accessibility for the ongoing US Leqembi launch. BioMarin Pharmaceutical (NASDAQ: BMRN) disclosed additional detail on the previously-announced Alesta Therapeutics acquisition (definitive agreement announced August 21): the transaction value is $275 million and the lead asset ALE1 is an oral hypophosphatasia (HPP) therapy that would challenge the currently-approved AstraZeneca / Alexion enzyme replacement Strensiq (asfotase alfa, a tissue-nonspecific alkaline phosphatase-Fc fusion protein) with a smaller-molecule oral format that could expand access to adult HPP patients where the injectable enzyme replacement has been less-broadly reimbursed. Johnson & Johnson (NYSE: JNJ) received FDA approval Wednesday August 26 for Imaavy (nipocalimab), an anti-FcRn monoclonal antibody, for warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 and older, extending the FcRn category that argenx pioneered with Vyvgart into a new autoimmune indication. And Chinese innovative drug developer Haisco Pharmaceutical Group entered an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners, extending the growing Chinese biotech pattern of ex-China commercialization partnerships alongside Hengrui-Kailera (ribupatide), Hanmi-Genentech (HM17321 UCN2), and Innovent's expanding US IND activity.

Industry

Eisai (TSE: 4523) and Biogen (NASDAQ: BIIB) Announced Wednesday August 26, 2026 That Once-Weekly Subcutaneous Lecanemab-Irmb (Brand Name Leqembi Iqlik) Is Now Commercially Available in the United States for Initiation Therapy in Adults With Early Alzheimer's Disease (Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease); The US Launch Represents the Anti-Amyloid Monoclonal Antibody Class's Substantive Transition From the Existing Twice-Monthly Intravenous Infusion Format to a Weekly Subcutaneous Injection That Substantially Improves Patient Accessibility and Reduces the Infrastructure Burden (Infusion Center Scheduling, Long Chair Time, IV Line Placement) That Has Constrained the Ongoing Global Leqembi Launch Since Initial 2023 FDA Approval

Eisai (TSE: 4523) and Biogen (NASDAQ: BIIB) announced Wednesday August 26, 2026 that once-weekly subcutaneous lecanemab-irmb (brand name Leqembi Iqlik) is now commercially available in the United States for initiation therapy in adults with early Alzheimer's disease (AD). Approved patient population: adults with mild cognitive impairment (MCI) or mild dementia due to AD, the same patient population that was approved for the IV formulation. Mechanism: lecanemab is a humanized IgG1 monoclonal antibody targeting soluble amyloid-beta protofibrils and preventing their aggregation into amyloid plaques that drive Alzheimer's pathology. Delivery format shift: the US launch represents the anti-amyloid class's substantive transition from the existing twice-monthly IV infusion format (requiring 1 hour of infusion time plus monitoring) to a weekly subcutaneous injection that substantially improves patient accessibility and reduces the infrastructure burden that has constrained the ongoing global Leqembi launch. Practical impact on Leqembi commercial trajectory: the SC format removes several barriers including infusion center scheduling constraints, long chair time per dose, and IV line placement complications. Eisai and Biogen have been struggling with slower-than-expected Leqembi launch since initial 2023 FDA approval due to reimbursement complexity, MRI monitoring requirements for amyloid-related imaging abnormalities (ARIA), and infrastructure requirements; the SC availability addresses one substantive barrier. Q2 2026 Leqembi worldwide sales reached roughly $340 million; the SC transition is expected to accelerate the commercial trajectory in Q4 2026 and into 2027.

#eisai #biogen #biib #leqembi #leqembi-iqlik #lecanemab #weekly-subcutaneous #alzheimer-disease #anti-amyloid #monoclonal-antibody #delivery-format-innovation #iv-to-sc #aria
Industry

BioMarin Pharmaceutical (NASDAQ: BMRN) Disclosed Wednesday August 26, 2026 Additional Detail on the Previously-Announced Alesta Therapeutics Acquisition (Definitive Agreement Announced August 21): The Transaction Value Is $275 Million and Alesta's Lead Asset ALE1 Is an Oral Hypophosphatasia (HPP) Therapy That Would Challenge the Currently-Approved AstraZeneca / Alexion Enzyme Replacement Strensiq (Asfotase Alfa, a Recombinant Tissue-Nonspecific Alkaline Phosphatase-Fc Fusion Protein Administered as Subcutaneous Injection) With a Smaller-Molecule Oral Format That Could Expand Access to Adult HPP Patients Where the Injectable Enzyme Replacement Has Been Less-Broadly Reimbursed; The Acquisition Continues BioMarin's Rare-Disease Portfolio Expansion Following the Amicus Integration Alongside Voxzogo (Vosoritide, C-Type Natriuretic Peptide Analog for Achondroplasia)

BioMarin Pharmaceutical (NASDAQ: BMRN) disclosed Wednesday August 26, 2026 additional detail on the previously-announced Alesta Therapeutics acquisition (definitive agreement announced August 21). Transaction value: $275 million. Alesta's lead asset ALE1: an oral hypophosphatasia (HPP) therapy in clinical development. Hypophosphatasia is a rare inherited metabolic disease caused by loss-of-function mutations in the ALPL gene encoding tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme required for bone mineralization and other biological processes; without adequate TNSALP activity, patients develop rickets, osteomalacia, seizures (in the severe perinatal form), and other complications. Commercial context: the currently-approved treatment is AstraZeneca / Alexion's Strensiq (asfotase alfa), a recombinant TNSALP-Fc fusion protein administered as three-times-weekly subcutaneous injection at a list price of approximately $1.5-2.0 million per adult patient per year. ALE1 would compete as a smaller-molecule oral format that could expand access to adult HPP patients where the injectable enzyme replacement has been less-broadly reimbursed by payers due to cost and administration burden concerns. The acquisition continues BioMarin's rare-disease portfolio expansion following the Amicus Therapeutics integration earlier in 2026 (which added GALAFOLD for Fabry disease and POMBILITI + OPFOLDA for late-onset Pompe disease) alongside Voxzogo (vosoritide, C-type natriuretic peptide analog for achondroplasia, on track for $1+ billion annual sales in 2026) and the broader enzyme-replacement franchise.

#biomarin-pharmaceutical #bmrn #alesta-therapeutics #ale1 #275-million-acquisition #hypophosphatasia #hpp #strensiq #asfotase-alfa #astrazeneca-alexion #oral-therapy #voxzogo #rare-disease-portfolio
Regulatory

Johnson & Johnson (NYSE: JNJ) Received FDA Approval Wednesday August 26, 2026 for Imaavy (Nipocalimab), an Anti-Neonatal Fc Receptor (FcRn) Monoclonal Antibody Administered as Subcutaneous Injection, for the Treatment of Warm Autoimmune Hemolytic Anemia (wAIHA) in Adults and Pediatric Patients Aged 12 and Older; wAIHA Is a Rare Autoimmune Disease in Which Autoantibodies (Primarily IgG) Bind Red Blood Cells at Body Temperature and Trigger Complement- and Macrophage-Mediated Red Blood Cell Destruction, Causing Fatigue, Jaundice, and in Severe Cases Life-Threatening Anemia; The Imaavy Approval Extends the Anti-FcRn Therapeutic Category That Argenx Pioneered With Vyvgart (Efgartigimod Alfa) Into a New Autoimmune Indication Beyond Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Johnson & Johnson (NYSE: JNJ) received FDA approval Wednesday August 26, 2026 for Imaavy (nipocalimab), an anti-neonatal Fc receptor (FcRn) monoclonal antibody administered as subcutaneous injection, for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 and older. Disease context: wAIHA is a rare autoimmune disease in which autoantibodies (primarily IgG) bind red blood cells at body temperature and trigger complement- and macrophage-mediated red blood cell destruction, causing fatigue, jaundice, splenomegaly, and in severe cases life-threatening anemia. Prior treatment has relied on corticosteroids, rituximab (an anti-CD20 monoclonal antibody), splenectomy, and other immunosuppressants, all with substantial side effects and variable efficacy. Nipocalimab mechanism: blocks the neonatal Fc receptor (FcRn) that normally rescues IgG antibodies from degradation; blocking FcRn accelerates IgG catabolism and reduces the pathogenic IgG autoantibody burden that drives wAIHA. The Imaavy approval extends the anti-FcRn therapeutic category that argenx pioneered with Vyvgart (efgartigimod alfa, IV and SC formulations) into a new autoimmune indication beyond the currently-approved indications of generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The FcRn category is a growing modality with multiple companies pursuing autoimmune indications; J&J's Imaavy is now approved for wAIHA and separately in myasthenia gravis, positioning as a direct competitor to argenx's Vyvgart franchise. Approval was supported by Phase 3 clinical data documenting substantial improvements in hemoglobin levels and transfusion-independence rates compared to placebo.

#johnson-johnson #jnj #imaavy #nipocalimab #anti-fcrn #monoclonal-antibody #warm-autoimmune-hemolytic-anemia #waiha #argenx #vyvgart #efgartigimod #autoimmune-disease #subcutaneous-injection
Industry

Chinese Innovative Drug Developer Haisco Pharmaceutical Group (SHE: 002653) Entered Wednesday August 26, 2026 an Exclusive Licensing Agreement With Sentivera, a Newly Formed US Venture Backed by Population Health Partners and ARCH Venture Partners, Extending the Growing Chinese Biotech Pattern of Ex-China Commercialization Partnerships Alongside Hengrui-Kailera (Ribupatide Triple Agonist Peptide, Global Phase 3 H1 2027), Hanmi-Genentech (HM17321 UCN2 Analog Peptide for Obesity, $190M Upfront + $2.3B Milestones, Announced August 24), and Innovent Biologics' Expanding US IND Activity (IBI3032 FDA IND Clearance August 5); Financial Terms and Specific Asset Details for the Haisco-Sentivera Agreement Have Not Been Fully Publicly Disclosed

Chinese innovative drug developer Haisco Pharmaceutical Group (SHE: 002653) entered Wednesday August 26, 2026 an exclusive licensing agreement with Sentivera, a newly formed US venture backed by Population Health Partners and ARCH Venture Partners. Financial terms and specific asset details for the Haisco-Sentivera agreement have not been fully publicly disclosed in initial press coverage; additional detail is expected in the deal filing documents. The transaction extends the growing Chinese biotech pattern of ex-China commercialization partnerships that has substantially accelerated across 2025 and 2026. Recent comparable transactions include: Hengrui Pharma to Kailera Therapeutics for ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist peptide, with Kailera's US Phase 3 planned H1 2027); Hanmi Pharm to Genentech for HM17321 (urocortin-2 analog peptide for obesity via CRFR2 receptor, $190 million upfront + up to $2.3 billion in milestones + tiered royalties, announced August 24); Innovent Biologics' IBI3032 receiving FDA IND clearance August 5 and multiple additional Chinese CDE implied licenses August 18 for synchronized dual-region development; and Minwei Bio's MWN105 Phase Ib registration August 19-20 targeting semaglutide-intolerant populations. The pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches, and it also reflects US venture capital interest in accessing Chinese-originated clinical-stage assets at attractive valuations relative to comparable US biotech candidates.

#haisco-pharmaceutical #sentivera #population-health-partners #arch-venture-partners #chinese-biotech-us-partnership #ex-china-licensing #hengrui-kailera #ribupatide #hanmi-genentech #hm17321 #innovent-biologics #ibi3032 #minwei-bio